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Abstract
Trichloroethylene (TCE) is a well-known environmental and occupational toxicant that is 
classified as carcinogenic to humans based on the epidemiological evidence of an association with 
higher risk of renal cell carcinoma. A number of scientific issues critical for assessing human 
health risks from TCE remain unresolved, such as the amount of kidney-toxic glutathione 
conjugation metabolites formed, inter-species and -individual differences, and the mode of action 
for kidney carcinogenicity. We hypothesized that TCE metabolite levels in the kidney are 
associated with kidney-specific toxicity. Oral dosing with TCE was conducted in sub-acute (600 
mg/kg/d; 5 days; 7 inbred mouse strains) and sub-chronic (100 or 400 mg/kg/d; 1, 2, or 4 weeks; 2 
inbred mouse strains) designs. We evaluated the quantitative relationship between strain-, dose-, 
and time-dependent formation of TCE metabolites from cytochrome P450-mediated oxidation 
[trichloroacetic acid (TCA), dichloroacetic acid (DCA), and trichloroethanol] and glutathione 
conjugation [S-(1,2-dichlorovinyl)-L-cysteine and S-(1,2-dichlorovinyl)glutathione], and various 
kidney toxicity phenotypes. In sub-acute study, we observed inter-strain differences in TCE 
metabolite levels in the kidney. In addition, we found that in several strains kidney-specific effects 
of TCE included induction of peroxisome proliferator-marker genes Cyp4a10 and Acox1, 
increased cell proliferation, and expression of KIM-1, a marker of tubular damage and 
regeneration. In sub-chronic study, peroxisome proliferator-marker gene induction and kidney 
toxicity diminished while cell proliferative response was elevated in a dose-dependent manner in 
NZW/LacJ, but not C57BL/6J mice. Overall, we show that TCE metabolite levels in the kidney 
are associated with kidney-specific toxicity and that these effects are strain-dependent.
Introduction
Trichloroethylene (TCE) is classified as ‘group 1 carcinogen’ by IARC (Guha et al. 2012) 
and as ‘carcinogenic to humans’ by the U.S. EPA (Chiu et al. 2013). These cancer 
classifications relied on human epidemiologic evidence linking exposures to TCE with renal 
cell carcinoma (Karami et al. 2012; Scott and Jinot 2011). In addition, the mutagenic mode-
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of-action (MoA) provides the biological plausibility to the human epidemiological findings 
(U.S. EPA 2011). The mechanistic and animal data that strengthens human evidence for the 
increased risk of renal cell carcinoma associated with exposures to TCE includes 
observations of an increase in kidney cancer incidence in male rats (National Toxicology 
Program 1988; National Toxicology Program 1990), qualitative similarities in TCE 
metabolism between rodents and humans (Chiu et al. 2006), genotoxic and mutagenic 
properties of glutathione (GSH)-conjugated metabolites of TCE (Moore and Harrington-
Brock 2000), and nephrotoxicity observed in mice treated with GSH conjugation 
metabolites (Shirai et al. 2012). Overall, evidence suggests that S-(1,2-dichlorovinyl)-L-
cysteine (DCVC), or its downstream reactive electrophile metabolites, may be responsible 
for kidney tumors in humans by a mutagenic MoA, as well as an MoA that involves 
cytotoxicity and compensatory cell proliferation (Rusyn et al. 2014).
The key role for GSH conjugation-derived TCE metabolites in the kidney effects of this 
toxicant is also supported by several mechanistic studies in humans. These include 
observation of a certain VHL tumor suppressor gene mutation pattern in TCE-exposed renal 
cell carcinoma cases (Brauch et al. 1999), an association between polymorphisms of 
GSTM1/GSTT1 and risk of renal cell cancer among workers exposed to TCE (Bruning et al. 
1997), and detection of S-(1,2-dichlorovinyl)glutathione (DCVG), a precursor of DCVC 
(Lash et al. 2014), in the blood of humans exposed to TCE (Lash et al. 1999). However, 
there are still many unresolved issues and uncertainties that reduce the confidence in these 
inferences. First, it is still debated whether or not the VHL mutation is an early event leading 
to TCE carcinogenesis. Induction of VHL mutation by TCE or its metabolites has not been 
experimentally demonstrated (Mally et al. 2006), and the association between VHL mutation 
and TCE exposure was not reproduced in similar human studies (Charbotel et al. 2007; 
Moore et al. 2011). Although additional evidence that the P81S missense mutation in VHL 
can mediate tumor growth was reported (Desimone et al. 2013), the relevance of VHL to the 
mechanisms of TCE carcinogenesis remains unclear.
A number of non-genotoxic mechanisms have been suggested as playing a role in TCE-
associated kidney cancer, but they lack evidence as strong as that for genotoxicity and 
mutagenicity of GSH conjugation metabolites of TCE. Proposed non-genotoxic mechanistic 
events include α2u-globulin-associated nephropathy, cytotoxicity not associated with α2u-
globulin-associated nephropathy, and peroxisome proliferator-activated receptor alpha 
(PPARα) activation (Rusyn et al. 2014). In addition, there is very limited data regarding the 
formation of GSH conjugation metabolites of TCE in tissues. Quantification of the 
metabolites is crucial not only for the toxicokinetic model-based extrapolation from rodents 
to humans, but also for addressing tissue/gender/species-specific toxicity of TCE. 
Metabolism is closely associated with the mode of action in TCE-induced cancer and non-
cancer effects as it was noted that the “knowledge of TCE metabolism is critical for 
determining susceptibility, target organ specificity and gender and species differences” 
(National Research Council 2006).
In this study, we tested a hypothesis that levels of GSH conjugation metabolites of TCE in 
the kidney are associated with kidney-specific toxicity in mice by evaluating the quantitative 
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relationship between strain-, dose-, and time-dependent formation of DCVG and DCVC, as 
well as various kidney toxicity phenotypes, in a panel of mouse inbred strains.
Materials and Methods
Animals and treatments
Male mice (aged 6–7 weeks) were purchased from the Jackson Laboratory (Bar Harbor, 
ME) and housed in polycarbonate cages on Sani-Chips (P.J. Murphy Forest Products Corp., 
Montville, NJ) irradiated hardwood bedding. Animals were fed NTP-2000 (Zeigler Brothers, 
Inc., Gardners, PA) wafer diet and water ad libitum on a 12 h light-dark cycle. All studies 
were approved by the UNC Institutional Animal Care and Use Committee.
Two study designs were utilized in this work. First, we performed a sub-acute study where 
vehicle (10 mL/kg, 5% Alkamuls EL-620 in saline) or TCE (600 mg/kg/d, in vehicle) was 
administered by gavage to mice from 7 inbred strains (129S1/SvImJ, A/J, BTBR T+tf/J, 
C57BL/6J, CAST/EiJ, NOD/ShiLtJ, and NZW/LacJ) for 5 consecutive days. These strains 
were selected to maximize inter-strain differences in metabolism of TCE based on the 
previous study of TCE metabolism in a panel of inbred strains (Bradford et al. 2011) and the 
results of the statistical modeling of the effect of time and strain on TCE metabolite 
concentrations which supports the sample size used in this study (Chiu et al. 2014). Second, 
based on the data from the sub-acute study, we selected two inbred strains (C57BL/6J and 
NZW/LacJ) that represented widely varying degrees of formation of oxidative metabolites 
of TCE for a subsequent sub-chronic study. Specifically, animals of each strain were 
randomly assigned to one of the three groups (5% Alkamuls EL-620 in saline vehicle, 100, 
or 400 mg/kg/day of TCE) and were dosed by oral gavage daily for 5 days/week for 1, 2, or 
4 weeks.
In all studies, mice were given drinking water containing 0.2 g/L of 5-bromo-2′-
deoxyuridine (BrdU) for 72 hrs prior to sacrifice. Blood, kidney and a section of a 
duodenum were collected 2 hrs after the last treatment. The timing of sacrifice was selected 
based on previous toxicokinetic studies of TCE in the mouse (Bradford et al. 2011; Kim et 
al. 2009b) showing that concentrations of both oxidative and glutathione conjugation 
metabolites of TCE peak around 2 hrs after dosing. Blood was drawn from vena cava and 
centrifuged to prepare serum using Z-gel tubes (Sarstedt, Germany) according to the 
manufacturer’s instructions. Blood urea nitrogen (BUN) and serum creatinine were 
quantified using QuantiChrom Urea Assay (BioAssay Systems, Hayward, CA) and 
Creatinine (serum) Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI), 
respectively. Body and organ weights were recorded. Kidney and duodenum sections were 
fixed in neutral buffered formalin for 24 hrs, and the remainder of the kidney tissue was 
frozen in liquid nitrogen. All serum and tissue samples were stored at −80°C until analyzed.
Quantification of TCE metabolites
Concentrations of trichloroacetic acid (TCA), dichloroacetic acid (DCA), DCVC, and 
DCVG in kidney were determined using HPLC-ESI-MS/MS as detailed elsewhere (Kim et 
al. 2009a) with slight modifications. Quantification of trichloroethanol (TCOH) in kidney 
Yoo et al. Page 3






















was performed using a method of (Song and Ho 2003). The configuration of the instruments 
was identical to that in the above mentioned references, but the extraction methods were 
optimized for each metabolite as follows.
TCA and DCA—Kidney samples (20 mg) were homogenized in 500 μL of 0.01 M PBS 
(pH 7.4) with 20 μL of internal standards (difluoroacetic acid and trifluoroacetic acid, 20 
nmol/mL each) using Tissuelyser (Qiagen, Valencia, CA) for 1 min. The homogenates were 
filter-centrifuged (Amicon Ultra Centrifugal Filters 10K; Millipore) at 14,000×g for 1 hr. 
After the filtrate was acidified with 100 μL of 3% (v/v) sulfuric acid, 2 mL of diethyl ether 
was added, and solutions were vortexed vigorously for 1 min. The upper ether layer was 
transferred to another vial, reduced in volume to less than 300 μL under continuous stream 
of N2, then transferred to a glass vial insert containing 5 μL of double-distilled water and 
dried completely. The residue was reconstituted in 20 μL of HPLC mobile phase consisting 
of 70% acetonitrile, 30% 1 mM ammonium citrate in double-distilled water. The lower limit 
of quantification (LLOQ) was 0.02 nmol/g kidney for DCA and 5 nmol/g kidney for TCA.
DCVG and DCVC—Kidney tissue (50 mg) was homogenized in 500 μL of methanol with 
20 μL of internal standards ([13C2,15N]DCVG and [13C3,15N]DCVC, 25 nmol/mL each) 
using Tissuelyser (Qiagen) for 1 min at 30/s. After adding 200 μL of chloroform, the 
homogenate was placed in shaker at 300 rpm for 10 min at 4°C, followed by centrifugation 
at 1,000×g for 5 min. The supernatant was then transferred to a new tube in which 200 μL of 
chloroform and 200 μL of water were added before centrifugation at 1,000×g for 5 min. 
From the upper aqueous phase, DCVG and DCVC were extracted using solid phase 
extraction (SPE) cartridge (StrataTM X-AW, 30mg 96-well plate; Phenomenex, Torrance, 
CA). After conditioning with 300 μL of methanol, followed by equilibration with 300 μL of 
water, the samples were loaded, washed with 300 μL of water, and finally eluted with 250 
μL of basic methanol (pH adjusted at 10.8 by 29.1% NH4OH). The final eluent was 
collected into 300 μL glass vial inserts and dried in a Speed Vac Concentrator before 
reconstitution with 20 μL of 4:1 water/methanol containing 0.1% acetic acid. The LLOQ 
was 1 pmol/g kidney for DCVG and 10 pmol/g kidney for DCVC.
TCOH—Kidney tissue (30 mg) was homogenized in 500 μL of acetate buffer (pH 4.6) with 
1,000 units of β-glucuronidase (cat. #G0751, Sigma, St. Louis, MO) using Tissuelyser 
(Qiagen) for 1 min, followed by overnight incubation at 37°C. After centrifugation at 
14,000×g for 5 min, the supernatant was transferred to a new tube, then mixed with internal 
standard (DCA, 10 mM in methanol, 20 μL) and 550 μL of water/0.1 M sulfuric acid/
methanol (6:5:1). The mixture was heated at 70°C for 20 min. After cooling to room 
temperature, 2.5 mL of hexane was added, the mixture was vortexed for 10 min and 
centrifuged at 2,500 g for 2 min. The upper layer was concentrated under N2 to less than 20 
μL and used for GC-MS analysis as detailed in (Song and Ho 2003). The LLOQ for TCOH 
was 15 nmol/g kidney.
Gene expression analysis by real-time PCR
Total RNA was isolated from kidney samples using an RNeasy kit (Qiagen) according to the 
manufacturer’s instructions. RNA concentration and quality were determined using an 
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ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE) and Agilent 2000 
Bioanalyser, respectively. Total RNA was reverse transcribed using random primers and the 
high capacity complementary DNA archive kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer’s protocol. The following gene expression assays (Applied 
Biosystems) were used for quantitative real-time PCR: peroxisome proliferator–activated 
receptor alpha (Pparα, Mm00440939_m1); palmitoyl acyl-Coenzyme A oxidase 1 (Acox1, 
Mm01246831_m1); cytochrome P450, family 4, subfamily a, polypeptide 10 (Cyp4a10, 
Mm01188913_g1); and beta glucuronidase (Gusb, Mm00446953_m1). Reactions were 
performed in a 96-well plate, and all samples were plated in duplicate using LightCycler® 
480 instrument (Roche Applied Science, Indianapolis, IN). The cycle threshold (Ct) for each 
sample was determined from the linear region of the amplification plot. The ΔCt values for 
all genes relative to the control gene Gusb were determined. The ΔΔCt were calculated using 
treated group means relative to strain-matched control group means. Fold change data were 
calculated from the ΔΔCt values.
Determination of proximal tubule cell proliferation
Deparaffinized and rehydrated kidney sections were immersed in 4N HCl and subsequently 
pepsin solution (Dako, Carpinteria, CA) for antigen retrieval and then incubated in 
peroxidase blocking reagent (Dako). Dako EnVision System HRP kit was used for the 
detection of BrdU-incorporated nuclei (monoclonal anti-bromodeoxyuridine antibody, 
Dako, 1:200 dilution). Data were presented as a fraction of BrdU staining-positive nuclei in 
the tubular epithelium of the renal cortex (no fewer than 1,000 nuclei counted per a kidney 
section).
Determination of KIM-1 expression in kidney
Detection of KIM-1 was accomplished by modifying a published method (Humphreys et al. 
2011). Formalin-fixed and paraffin-embedded kidney sections were deparaffinized and 
rehydrated. Antigens were retrieved by 4N HCl and pepsin solution (Dako) afterward. After 
peroxidase blocking, immunohistochemical detection was conducted using Dako Liquid 
DAB Substrate Chromogen System with primary anti KIM-1 antibody (2 ug/mL in PBS) 
(R&D Systems, Minneapolis, MN) and secondary goat IgG HRP-conjugated Antibody 
(1:100 in PBS) (R&D Systems). The proportion of positive-stained proximal tubules in outer 
medulla was determined under light microscopy. Data were presented as a fraction of 
proximal renal tubules staining positive for KIM-1 (no fewer than 200 proximal renal 
tubules counted per a kidney section).
Statistical analyses
The significance of inter-strain effect on metabolism was assessed by ANOVA modeling. 
Given the small sample size, the exact permutation test was used to determine significant 
differences between control and TCE-treated groups (α=0.05). The Spearman (rank) 
correlation analysis across all variables was conducted to account for the difference in scale 
of the variables. In correlation analyses, false discover rate correction (Storey and Tibshirani 
2003) was applied to all p-values to correct for multiple comparisons. The resultant 
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significant (<0.1) q-values are reported in the Supplementary Tables. All statistical analyses 
were performed using SAS software ver. 9.3 (SAS Institute, Cary, NC).
Data availability
Individual animal-level data for all quantitative endpoints is available publicly at the Mouse 
Phenome Database (http://phenome.jax.org/; accession ID: Rusyn6).
Results
Sub-acute (5 days) study of strain-dependent effects of TCE in mouse kidney
We measured kidney levels of TCE metabolites from CYP450-mediated oxidation (TCA, 
DCA, TCOH) and GSH conjugation (DCVC and DCVG) in mice from seven inbred strains 
treated with an aqueous suspension of TCE (600 mg/kg/d) for 5 days (Figure 1). Across all 
strains, kidney levels of TCA were 100 to 1,000-fold greater than those for DCA, and the 
amounts of DCA were about 100 to 1,000-fold higher than those of either DCVG or DCVC. 
Mouse kidney levels of TCOH, also a major oxidative metabolite of TCE, were 2 to 4-fold 
higher than those of TCA. The concentration of DCVC in kidney was at least 50 to 100-fold 
higher than that of DCVG, which was below the LLOQ in most samples. We found a 
significant strain effect (p<0.05) for each metabolite. Liver and serum concentrations of 
these metabolites are reported in a companion manuscript (Yoo et al. submitted).
We examined the correlation between TCE metabolites in mouse kidney, liver, and serum 
(Supplementary Table 1). We observed no significant correlation among metabolites in the 
kidney. However, we found an inter-organ correlation for GSH conjugation-derived TCE 
metabolites. Although DCVG and DCVC were not correlated with each other in either liver 
or kidney, we found a significant correlation between liver DCVG, and kidney and serum 
DCVC, as well as with kidney DCVG, even after correction for multiple comparisons. Liver 
DCA correlated significantly with serum, liver and kidney TCA.
We examined effects of repeat dosing with TCE on kidney weight (relative to body weight), 
proximal tubule cell proliferation, and BUN (Figures 2A–C). We observed significant effect 
on kidney enlargement in response to sub-acute treatment with TCE in 129S1/SvImJ and 
BTBR T+tf/J strains; however, proximal tubule cell proliferation, as evaluated by BrdU 
immunohistochemistry, was not affected by TCE in any strain. BUN levels did not change 
in response to TCE treatment.
Given the large amounts of CYP450-mediated oxidative metabolites and the strain-
dependent kidney enlargement, we evaluated kidney expression of Pparα, as well as 
Cyp4a10 and Acox1, marker genes for PPARα activation (Figures 2D–F). We observed 
significant exposure-related increases in expression of the transcription factor Pparα in 
NOD/ShiLtJ and NZW/LacJ strains. TCE had a significant effect of expression of Acox1 
only in NOD/ShiLtJ, while expression of Cyp4a10 was significantly elevated in four strains 
including C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, and NZW/LacJ. Where induced by TCE, 
the magnitude of the effect on Cyp4a10 was found to be much greater than that on Acox1.
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Histopathological evidence of kidney injury was previously observed in mice exposed to 
TCE sub-acutely or sub-chronically only at very high doses (in excess of 3,000 mg/kg) 
(National Cancer Institute 1976; National Toxicology Program 1990). Recently, KIM-1 was 
qualified as a sensitive and early biomarker of acute kidney injury (Ozer et al. 2010). 
Therefore, we examined KIM-1 expression and found that TCE significantly induced 
expression of KIM-1 on the apical membrane of the proximal tubular S3 segment in the 
outer medulla in 129S1/SvImJ, C57BL/6J, A/J, and BTBR T+tf/J strains (Figure 3).
Because inter-strain differences in both TCE metabolism and kidney toxicity were observed 
in this study, we examined correlations among these endpoints in kidney (Supplementary 
Table 2). Liver DCVG and kidney DCVC are significantly correlated (Figure 4A). Also, 
Acox1 and Cyp4a10 were significantly correlated with each other (Figure 4B). We found no 
significant correlation between kidney levels of DCVC and expression of either Acox1 or 
Cyp4a10 (Figure 4C). KIM-1 expression was not significantly correlated with any TCE 
metabolite, including DCVC (Figure 4D), or other endpoints such as markers of PPARα 
activation.
Sub-chronic (up to 4 weeks) study of strain-dependent effects of TCE in mouse kidney
Based on the differences in TCE metabolism observed in the sub-acute (5 days) TCE 
exposure study, we selected C57BL/6J and NZW/LacJ strains to further test our hypothesis 
that inter-strain differences in formation of GSH-conjugation metabolites of TCE in the 
kidney are associated with kidney-specific toxicity. We examined time- (1, 2 and 4 weeks) 
and dose-dependent (100 and 400 mg/kg/d, i.g.) effects of TCE in these two strains.
We found that strain-dependent differences in TCA level in kidney are dose-dependent 
(Figure 5). Overall, kidney levels of TCA and TCOH were higher in NZW/LacJ mice, 
similar to the sub-acute study result (Figure 1). Also, concordant with the findings in the 
sub-acute study, levels of TCA and TCOH in kidney were 100 to 1,000-fold greater than 
those of DCA. Levels of DCVC and DCVG in kidney were below the LLOQ; however, the 
doses of TCE used herein were lower than those in the sub-acute study. Amounts of 
CYP450-depedent oxidative metabolites of TCE in the kidney generally trended downward 
over time. Specifically, the levels of TCA in kidney decreased over time in both strains, 
while the level of TCOH in kidney decreased over time only in C57BL/6J strain, which was 
consistent with the findings in the liver. We found no dose-, time-, or strain-dependent 
differences in kidney levels of DCA.
Among CYP450-dependent oxidative metabolites that were quantified in this study, kidney 
levels of TCA and TCOH were highly correlated (Supplemental Table 3) across both strains 
in the sub-chronic study. Interestingly, kidney levels of TCA and TCOH were significantly 
correlated with liver levels of TCA, DCA, and TCOH, which may reflect the strong 
decreasing trend in formation of CYP450-depedent oxidative metabolites of TCE over time 
that was observed both in the liver and kidney.
We also examined the effects of sub-chronic treatment with TCE on the kidney toxicity 
markers and the marker genes of PPARα activation. We found no effect of sub-chronic TCE 
treatment on kidney in terms of traditional biomarkers such as kidney-to-body weight ratio, 
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BUN, and serum creatinine (Figures 6A–C). However, we observed a prominent effect of 
TCE on the marker genes of PPARα activation in the kidney. Expression of Acox1 and 
Cyp4a10 significantly increased in a dose-dependent manner in both strains of mice treated 
with TCE for 5 days (Figures 6E–F). Pparα was also significantly induced by TCE in NZW/
LacJ mice at the highest dose at 5 days. Interestingly, the extent of up-regulation of Acox1 
and Cyp4a10 by TCE decreased over time. In the 2 and 4 weeks treatment groups, we found 
little to no differences in gene expression between vehicle and TCE-treated animals, except 
for significant induction of Pparα and Acox1 in C57BL/6J mice treated with 400 mg/kg/d 
TCE for 2 weeks.
Furthermore, we observed that effects of TCE on proximal tubule cellular proliferation and 
KIM-1 expression were treatment-, time- and strain-dependent (Figure 7). Whereas we 
found that the proximal tubule cellular proliferation was significantly elevated only in NZW/
LacJ strain after 4 weeks of treatment with TCE, a significant increase in KIM-1 expression 
was observed in both strains only after 5 days of treatment with TCE.
We found that kidney levels of TCA were significantly correlated with TCOH (Figure 8A), 
and Acox1 and Cyp4a10 expression in the kidney regardless of TCE dose or treatment 
duration (Figure 8B). We also observed that kidney levels of TCA were significantly 
correlated with expression of KIM-1 (Figure 8C), but not with proximal tubule cellular 
proliferation (Figure 8D).
Discussion
This study is first to report the levels of CYP-mediated oxidative and GSH-conjugation 
metabolites of TCE in the kidney of exposed mice. The estimation of the relative flux to 
each of these two pathways of TCE metabolism has been subject to debate (Rusyn et al. 
2014). Although recent human cancer hazard assessments concluded that GSH conjugation 
pathway is primarily responsible for TCE-induced kidney effects (Chiu et al. 2013; Guha et 
al. 2012), there are considerable uncertainties regarding the extent of the flux to GSH 
conjugation pathway between species and among individuals. Thus, we aimed to provide 
quantitative estimates of dose-, time-, and strains-specific differences in TCE metabolite 
burden in the mouse kidney, and to determine whether TCE-associated toxicity phenotypes 
correlate with TCE metabolite levels. Not only does this study provide for the first time 
comprehensive quantitative estimates of TCE metabolism and toxicity in kidney of mouse as 
species, but also it explored inter-strain variability in these phenotypes. Indeed, a mouse 
model of the human population is an effective tool for understanding the molecular 
underpinnings of the population variability in response to toxic agents (Rusyn et al. 2010), 
including studies of adverse health effects of chlorinated solvents (Bradford et al. 2011).
Species comparison of TCE metabolite levels in the kidney
In the sub-acute study, similar with the findings in the liver (Yoo et al, submitted), we found 
up to 5 orders of magnitude difference in the relative flux of TCE through CYP450-
dependent oxidation (primarily TCA) as compared to GSH conjugation in mouse kidney. 
These findings are consistent with the TCE metabolite data in mouse serum (Kim et al. 
2009b; Bradford et al. 2011; Chiu et al. 2014). However, our findings differ from those 
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reported in one rat study where kidney levels of TCE metabolites were evaluated (Lash et al. 
2006). Lash et al. (2006) reported kidney levels of DCVG in female rats to be 100-fold 
higher than those of TCA and TCOH. Furthermore, kidney levels of DCVC in female rats in 
Lash et al. (2006) were similar to those observed in our study in male mice, but the levels of 
DCVG reported in female rat kidneys were about 10-fold greater. No DCVG or DCVC were 
detected in male rat kidneys by Lash et al. (2006).
A criticism of the technical issues that accompany the methodology for detection of GSH 
conjugation metabolites of TCE used in the studies of Lash and co-workers has been 
detailed in (U.S. EPA 2011), and it was argued that the technique of (Fariss and Reed 1987) 
may overestimate the amounts of DCVG. The major differences in the relative flux through 
the oxidative and GSH conjugation pathways are, however, due to much lower amounts of 
TCA reported by Lash et al (2006). Furthermore, these results are not in accord with 
published reports of blood or plasma levels of TCE-derived DCA and TCA in rat and mouse 
(Kim et al. 2009a; Abbas and Fisher 1997; Merdink et al. 1998; Larson and Bull 1992). 
Thus, the toxicological implications of the quantitative difference among studies and species 
should be interpreted with caution. We reason that our results on TCE metabolite levels in 
mouse kidneys provide valuable new data that fill a gap in organ-specific health assessments 
of TCE and related solvents.
Intra- and inter-organ metabolism of TCE
We also found that the effect of the first-pass metabolism of TCE in the liver may be still 
sustained in the kidney. TCA and TCOH are two major TCE metabolites to be excreted, and 
we found that kidney levels of TCOH were 2 to 3-fold higher than those of TCA, which is in 
accord with the observation that cumulative urinary excretion of TCOH was about 2-fold 
higher than that of TCA in humans exposed to chloral hydrate (Merdink et al. 2008). A 
significant correlation between liver DCVG and kidney DCVC also supports a hypothesis 
that DCVG is primarily formed in the liver and then translocates to the kidney, where 
subsequent metabolism to DCVC involves γ-glutamyltransferase and cysteinylglycine 
dipeptidase (Lash et al. 1998).
With respect to inter-organ differences in CYP450-dependent oxidation, we found no 
relationship between liver and kidney, other than significant correlation between liver DCA 
and kidney TCA in a sub-acute study, possibly due to strain-difference in metabolism and 
transport. However, in a sub-chronic study, liver levels of TCA, DCA, and TCOH were 
significantly correlated with kidney levels of TCA, DCA, and TCOH. This finding suggests 
effective inter-organ transport of the oxidative metabolites of TCE. Among GSH 
conjugation metabolites of TCE, the only significant correlation found was between liver 
DCVG and kidney DCVC. This correlation, combined with the observations that DCVG is 
detected in much greater concentrations in the liver than DCVC, and that the opposite is true 
in the kidney, strongly supports the dependence of the downstream metabolism of DCVG on 
kidney-specific enzymes (Lash et al. 2000).
For the sub-chronic study, C57BL/6J and NZW/LacJ strains were selected to maximize the 
strain differences in the extent of TCE metabolism. One of the notable differences between 
these two strains is the relative difference in flux to each pathway. As expected from the 
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data in the sub-acute study, kidney levels of TCA and TCOH were found to be higher in 
NZW/LacJ than in C57BL/6J mice. However, DCVC and DCVG, which were expected to 
be higher in C57BL/6J, were not detected in the sub-chronic study where the doses used 
were lower than those in the sub-acute study. The sensitivity of the analytical methods, 
combined with low extraction recoveries, presents a continued limitation to our ability to 
quantify the levels of these critically important TCE metabolites in studies that use 
environmentally-relevant exposures to TCE. Therefore, further improvements are needed to 
fill the data gaps.
TCE-induced kidney toxicity
Our study provides important information on the TCE-associated increase in relative kidney 
weight and acute kidney injury. The finding that relative kidney weight and KIM-1 
expression, an indicator of both damage and regeneration (Ichimura et al. 2004), were 
increased in response to sub-acute TCE treatment in some, but not all mouse strains, 
provides additional direct evidence that TCE can cause nephrotoxicity in the mouse, but that 
this effect is strain-dependent. Another sub-acute (10 days) study with TCE found no 
significant increases in kidney/body weight ratios in B6C3F1 mice (Goldsworthy and Popp 
1987). Depletion of GSH in the renal cortex of NMRI mice treated with a single i.p. dose of 
TCE was also shown (Cojocel et al. 1989). Mild to moderate cytomegaly and karyomegaly 
of the renal tubular epithelial cells of the inner cortex were observed in some, but not all, 
male B6C3F1 mice treated for 13 weeks with 3000 or 6000 mg/kg/d TCE (National 
Toxicology Program 1990). In our study, an increase in KIM-1 expression was observed in 
4 out of 7 strains treated with TCE (600 mg/kg/d) for 5 days, and confirmed in the two 
strains treated with TCE (400 mg/kg/d) for 5 days in the sub-chronic study. We found no 
positive KIM-1 signal with or without TCE treatment in NOD/ShiLtJ strain in which 
relatively higher amount of kidney DCVC was detected; however, NOD/ShiLtJ mice appear 
to be uniquely resistant to kidney injury as even upon treatment with a known renal toxicant 
DB289 no increase in urinary KIM-1 was detected, while in C57BL/6J mice a 10-fold 
increase was observed (Harrill et al. 2012).
Interestingly, at both 2 and 4 week treatment time points, KIM-1 expression was not 
significantly increased, albeit it was somewhat higher in TCE-treated NZW/lacJ mice. This 
dampening of the nephrotoxicity under conditions of the continuous exposure may be due to 
the compensatory responses of the kidney. Indeed, tubular epithelial cells can undergo 
compensatory proliferation and adaptation following injury (Lin et al. 2005; Duffield et al. 
2005).
TCE effects on PPARα-associated pathways
Limited evidence exists to suggest that TCE exposure induces peroxisome proliferation in 
the kidney of exposed rodents. Peroxisome proliferation in the rat and mouse kidney has 
been evaluated in only one other study (Goldsworthy and Popp 1987) where animals were 
exposed to TCE (1000 mg/kg/d) for 10 days. Increases in renal palmitoyl–CoA oxidation 
activity were observed in both rats and mice treated with TCE. We show that treatment with 
a comparable dose of TCE (600 mg/kg/d) for 5 days resulted in induction of Cyp4a10 that 
was significant in 4 out of 7 strains tested. Acox1 and Pparα were also markedly induced in 
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NOD/ShiLtJ strain, in which Cyp4a10 induction was almost 100-fold. Marked strain-
dependence of the TCE effect on PPARα-mediated signaling in mouse kidney is similar to 
that in the liver, as it was found that PPAR-mediated pathway was one of the most 
pronounced strain-dependent molecular effects of TCE in mouse liver (Bradford et al. 
2011).
In the sub-chronic study, not only did we observe dose- and strain-specific effects on the 
same endpoints, but we also found a decreasing trend of Acox1 and Cyp4a10 expression 
over time in the kidney. There is a similar observation in a time-course study with a model 
peroxisome proliferator di-2-ethylhexyl phthalate (Ohno et al. 1982). The authors counted 
the number of peroxisomes in the kidney cortex of rats exposed to DEHP and found that the 
number of peroxisomes peaked at 1 week and decreased at 2 and 4 weeks. Similar to the 
effects of TCE in the liver, it is likely that this dampening of an effect is related to a 
decrease in the amount of CYP450-mediated oxidative metabolites of TCE. Indeed, there 
was a significant correlation among kidney levels of TCA and expression of both Acox1 and 
Cyp4a10.
TCE metabolite levels and kidney toxicity phenotypes
In addition, the data collected in this study allows for a detailed quantitative investigation of 
the relationships between TCE metabolite levels and kidney toxicity phenotypes. While 
CYP450-mediated oxidative metabolites of TCE are known to activate PPARα signaling, 
and the GSH conjugation metabolite, DCVC has been shown to be nephrotoxic in mice 
(Jaffe et al. 1985; Darnerud et al. 1989), no previous study examined the correlation between 
metabolism and toxicity. Indeed, a number of confirmatory and novel observations were 
drawn from such comparisons in the work presented herein.
In the sub-acute study, the strain-dependent minimal to mild nephrotoxicity, as evidenced by 
KIM-1 immunohistochemistry, did not correlate with any measured TCE metabolites, 
including DCVC. In the sub-chronic study, KIM-1 staining in proximal tubules, a marker of 
both cytotoxicity and regeneration was correlated with kidney amounts of TCA. These 
findings suggest that multiple metabolites and/or pathways are likely to be involved in TCE-
induced kidney cytotoxicity in mice. In fact, evidence of cytotoxicity in the rat kidney was 
observed not only in animals treated with DCVC, but also those treated with TCA and 
TCOH (Green et al. 2003; Dow and Green 2000). Renal toxicity in long-term studies in rats 
has been attributed to stimulation of formic acid excretion by oxidative metabolites of TCE 
(Green et al. 1998). The reported connection between formic acid excretion, acidosis, renal 
toxicity and renal cancer in rats exposed to trichloroethylene for 2 years has not been 
explored yet in mice and our data suggest that this mechanism may also be plausible.
In the sub-acute study, we did find a similar strain- and treatment-dependent pattern between 
the level of DCVC and expression of Cyp4a10, although the correlation was not significant 
in part due to the small number of data points. This is a noteworthy finding because 
CYP450-mediated oxidative, but not GSH conjugation, metabolites are regarded as 
responsible for PPARα activation, although the data in the kidney is limited. TCA, but not 
DCVC, was strongly correlated with Acox1 and Cyp4a10 in the sub-chronic study; however, 
this correlation may primarily reflect the decreasing trend over time observed 
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simultaneously in the levels of metabolites and the extent of PPARα activation. When the 
data is stratified by strain, the levels of TCA and TCOH were higher in NZW/LacJ, while 
the extent of PPARα target gene expression was higher in C57BL/6J in both sub-acute and 
sub-chronic studies. This result questions a direct relationship between formation of 
oxidative metabolites and PPARα activation in the mouse kidney. PPARα activation has 
important roles in renal function, such as maintenance of energy balance through regulating 
β-oxidation of fatty acids (Portilla et al. 2000), blood pressure regulation linked with 
CYP450 4A enzyme (Guan and Breyer 2001), and peroxisomal respiration associated with 
oxidative stress (Zaar 1992). Just as the perturbation of PPARα activity may result in 
various adverse effects, so a number of endogenous and exogenous factors can induce 
PPARα activation (Peters et al. 2012).
We also note that the correlation analyses performed herein, while highly informative, have 
limitations as they do not take into consideration potential differences in clearance between 
the different metabolites, across strains, and effects of TCE treatment. In addition, the 
concentration-time profiles of different metabolites in serum vary greatly (Kim et al 2009b) 
and our study collected metabolite data only at one time point, two hours prior to sample 
collection, whereas the toxicity effects are likely to be the cumulative result of treatments on 
the previous days, as well as that prior to sample collection.
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Figure 1. Inter-strain variability in TCE metabolism in the kidney of mouse in a sub-acute study
Kidney levels of metabolites were assessed 2 h following the last of 5 daily doses (600 
mg/kg/d) of TCE. Box and whisker plots are shown (+, mean; line, median; box, inter-
quartile range; whiskers, min to max). When box is shown, 4 animals per group were 
available. Otherwise, there were 3 animals per group.
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Figure 2. Inter-strain differences in kidney toxicity of TCE in a sub-acute study
(A) Kidney to body weight ratios, (B) percent BrdU-positive proximal tubule cell nuclei, (C) 
blood urea nitrogen, and kidney expression of peroxisome proliferation marker genes Ppara 
(D), Acox1 (E), and Cyp4a10 (F) were evaluated in mice treated with vehicle (white) or TCE 
(gray; 600 mg/kg) for 5 days. Box and whiskers plots are shown (+, mean; line, median; 
box, inter-quartile range; whiskers, min to max). Asterisk (*) denotes a significant difference 
(p<0.05) compared to vehicle-treated group within same strain. When box is shown, 4 
animals per group were available. Otherwise, there were 3 animals per group.
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Figure 3. Inter-strain differences in KIM-1 expression in mouse kidney in a sub-acute study
Immuno-histochemical detection of KIM-1 (brown deposits on the apical membrane side of 
kidney proximal tubules in the outer medulla) was performed. Representative images from 
vehicle (left) and TCE (600 mg/kg/d for 5 days)-treated CAST/EiJ (A) and C57BL/6J strains 
are shown. (C) Quantitative analysis of KIM-1-positive proximal tubules in the kidneys of 
mice treated with vehicle (white) or TCE (gray). Box and whiskers plots are shown (+, 
mean; line, median; box, inter-quartile range; whiskers, min to max). Asterisk (*) denotes a 
significant difference (p<0.05) compared to vehicle-treated group within same strain. There 
were 4 animals per group.
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Figure 4. Correlation among kidney DCVC and toxicity phenotypes in a sub-acute study
(A) DCVG in the liver was significantly correlated with the kidney levels of DCVC. (B) 
Kidney expression of Cyp4a10 and Acox1 were significantly correlated. (C) TCE-induced 
increase in Cyp4a10 (open circle) and Acox1 (filled rhombus) expression in the mouse 
kidney was not significantly correlated with kidney level of DCVC. (D) No significant 
correlation was observed between DCVC concentration in the kidney and KIM-1 
expression. Each dot represents an individual TCE-treated animal in the study. Spearman 
rank (ρ) correlations and false discovery rate-corrected significance values (q<0.1) are 
shown.
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Figure 5. Time-course analysis of TCE metabolism in C57BL/6J and NZW/LacJ mice in a sub-
chronic study
TCA (A), DCA (B), and TCOH (C) levels in the kidney were assessed 2 h following the last 
dose after 1, 2 or 4 wks (100 or 400 mg/kg/d) of TCE. Box and whiskers plots are shown (+, 
mean; line, median; box, inter-quartile range; whiskers, min to max). Light-gray, 100 
mg/kg/d groups; dark gray, 400 mg/kg/d groups. Asterisks denote a significant (p<0.05) 
difference as compared to (*) the group dosed with 100 mg/kg/d (same strain and time 
point), or (#) the 5 day treatment group (same strain and dose). Box and whiskers plots are 
shown (+, mean; line, median; box, inter-quartile range; whiskers, min to max). When box is 
shown, 5 animals per group were available. Otherwise, there were 3 animals per group.
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Figure 6. Differences in kidney toxicity of TCE in C57BL/6J and NZW/LacJ mice in a sub-
chronic study
Kidney to body weight ratios (A), blood urea nitrogen (B), serum creatinine (C), and kidney 
expression of peroxisome proliferation marker genes Ppara (D), Acox1 (E), and Cyp4a10 
(F) were evaluated in mice treated with TCE (100 or 400 mg/kg) for 1, 2 or 4 wks. Box and 
whiskers plots are shown (+, mean; line, median; box, inter-quartile range; whiskers, min to 
max). White, vehicle-treated groups; light-gray, 100 mg/kg/d groups; dark gray, 400 
mg/kg/d groups. Asterisk (*) denotes a significant (p<0.05) difference as compared to 
vehicle-treated group (same strain and time point). Thickness of the line corresponds to the 
vehicle, 100 and 400 mg/kg/d groups. Box and whiskers plots are shown (+, mean; line, 
median; box, inter-quartile range; whiskers, min to max). When box is shown, 5 animals per 
group were available. Otherwise, there were 3 animals per group.
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Figure 7. Differences in kidney toxicity of TCE in C57BL/6J and NZW/LacJ mice in a sub-
chronic study
Percent BrdU-positive proximal tubule cell nuclei (A), and kidney expression of KIM-1 (B) 
were evaluated in mice treated with TCE (100 or 400 mg/kg/d) for 1, 2 or 4 wks. Box and 
whiskers plots are shown (+, mean; line, median; box, inter-quartile range; whiskers, min to 
max). White, vehicle-treated groups; light-gray, 100 mg/kg/d groups; dark gray, 400 
mg/kg/d groups. Asterisk (*) denotes a significant (p<0.05) difference as compared to 
vehicle-treated group (same strain and time point). Box and whiskers plots are shown (+, 
mean; line, median; box, inter-quartile range; whiskers, min to max). When box is shown, 5 
animals per group were available. Otherwise, there were 3 animals per group.
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Figure 8. Correlation between TCE metabolites and kidney toxicity phenotypes in C57BL/6J and 
NZW/LacJ mice in a sub-chronic study
(A) Levels of TCA and TCOH in kidney were significantly correlated with each other. (B) 
TCE-induced increase in Cyp4a10 (open circle) and Acox1 (filled rhombus) expression in 
the mouse kidney was significantly correlated with kidney levels of TCA. (C) Levels of 
TCA in the kidney were significantly correlated with KIM-1 expression in the proximal 
tubules. (D) No correlation was observed between TCA concentrations in the kidney and 
proximal tubule cellular proliferation. Each dot represents an individual TCE-treated mouse. 
Spearman rank (ρ) correlations and false discovery rate-corrected significance values 
(q<0.1) are shown.
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